US · CRMD
CorMedix Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Berkeley Heights, NJ 07922
- Website
- cormedix.com
Price · as of 2024-12-31
$7.79
Market cap 561.77M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $77,885.15 | +999,709.37% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $8.45 | ||||
| 2011 | $1.75 | ||||
| 2012 | $4.40 | ||||
| 2013 | $14.05 | ||||
| 2014 | $42.00 | $1,271.63 | $0.00 | $0.00 | $0.00 |
| 2015 | $12.45 | $47.57 | $3.19 | $0.00 | $0.00 |
| 2016 | $10.60 | $28.44 | $7.38 | $0.00 | $0.00 |
| 2017 | $1.60 | $20.65 | $29.53 | $0.00 | $0.00 |
| 2018 | $8.90 | $32.83 | $74.96 | $0.00 | $0.00 |
| 2019 | $5.83 | $37.82 | $0.00 | $0.00 | $16.60 |
| 2020 | $9.31 | $25.07 | $0.67 | $0.00 | $5.24 |
| 2021 | $4.85 | $27.12 | $0.89 | $0.00 | $8.39 |
| 2022 | $3.74 | $28.93 | $0.77 | $0.00 | $40.56 |
| 2023 | $3.68 | $30.67 | |||
| 2024 | $10.71 | $6.48 | $0.00 |
AI valuation
Our deep-learning model estimates CorMedix Inc.'s (CRMD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $7.79
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$77,885.15
+999,709.37% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CRMD | CorMedix Inc. | $7.79 | 561.77M | — | +999,709% | — | — | -35.17 | 7.45 | 14.50 | -30.53 | — | 7.61 | 92.66% | -51.43% | -41.24% | -23.17% | -146.77% | -17.85% | 0.01 | -614.10 | 3.39 | 3.05 | 2.11 | -6703.00% | — | 3096.00% | -8.05% | -1.50 | -358.96% | 0.00% | 0.00% | 0.00% | -25.91 | -11.42 | 13.33 | 7.62 |
| ABUS | Arbutus Biopharma Corpora… | $4.66 | 896.23M | +556% | -71% | — | +345% | -8.79 | 6.31 | 99.56 | -7.21 | — | 6.31 | 100.00% | -1236.74% | -1133.04% | -68.76% | 433.24% | -50.65% | 0.01 | -557.07 | 8.15 | 8.01 | 0.51 | -1364.00% | -6598.00% | -2520.00% | -10.59% | -4.15 | 369.16% | 0.00% | 0.00% | 2.84% | -6.46 | -7.58 | 79.89 | -4.43 |
| BCAX | Bicara Therapeutics Inc. … | $16.78 | 919.24M | — | — | — | — | -13.25 | 1.83 | — | -5.00 | -52.99 | 1.83 | 0.00% | — | — | -19.14% | 1967.97% | -16.93% | 0.00 | — | 27.93 | 27.22 | 5.94 | 2500.00% | — | 6190.00% | -8.31% | -4.16 | 1787.22% | 0.00% | 0.00% | 28.78% | -5.00 | -5.50 | — | 6.99 |
| EYPT | EyePoint Pharmaceuticals,… | $17.56 | 1.45B | +9,195% | -75% | — | — | -3.07 | 1.19 | 9.28 | -0.41 | -11.16 | 1.19 | 91.42% | -337.06% | -302.43% | -43.42% | 403.05% | -33.83% | 0.06 | -10418.14 | 7.81 | 7.57 | 0.60 | 2747.00% | -597.00% | 800187.00% | -32.46% | -2.57 | 360.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 1.21 | -0.07 |
| KURA | Kura Oncology, Inc. | $8.73 | 759.66M | — | — | — | — | -3.73 | 1.57 | 12.04 | 0.37 | — | 1.57 | 100.00% | -358.55% | -322.89% | -42.91% | 126.01% | -28.78% | 0.04 | -119.33 | 9.46 | 9.24 | 1.23 | -288.00% | — | -20708.00% | 20.63% | 1.71 | -87.30% | 0.00% | 0.00% | 28.94% | 0.32 | -0.46 | -1.15 | -0.24 |
| NBTX | Nanobiotix S.A. | $31.04 | 1.5B | +16% | -96% | — | +542% | -1.99 | -2.06 | -11.65 | -2.34 | -5.96 | -2.06 | 100.00% | 589.13% | 586.89% | 201.73% | 150.15% | -84.47% | -0.77 | -8.46 | 1.04 | 0.99 | -0.02 | 3333.00% | -13206.00% | 5921.00% | -15.08% | -0.33 | 44.78% | 0.00% | 0.00% | 0.00% | -2.00 | -6.69 | -11.75 | -4.28 |
| PROK | ProKidney Corp. | $2.24 | 277.76M | — | — | — | — | -0.63 | -0.10 | 1352.79 | 1.59 | -7.18 | -0.10 | 100.00% | -241678.95% | -80507.89% | 15.57% | 13.02% | -37.91% | 0.00 | -20408.44 | 10.93 | 9.96 | 0.60 | 877.00% | — | 2542.00% | -151.60% | -3.49 | 11.09% | 0.00% | 0.00% | 38.56% | 1.37 | 1.62 | -3319.00 | -2.64 |
| PVLA | Palvella Therapeutics, In… | $135.02 | 1.6B | — | — | — | — | -3.70 | 1.03 | — | 1.45 | — | 1.03 | 0.00% | — | — | -59.37% | 87.48% | -36.40% | 0.00 | -3.26 | 7.33 | 7.14 | 6.37 | -15312.00% | — | -2089.00% | -16.79% | -0.90 | 67.28% | 0.00% | 0.00% | 118.12% | 1.35 | 1.76 | — | 0.53 |
| SEPN | Septerna, Inc. | $29.02 | 1.3B | +1,403% | -60% | -79% | — | -0.89 | 0.15 | 59.16 | 3.30 | — | 0.15 | 100.00% | -7518.42% | -6678.88% | -37.62% | 815.26% | -24.45% | 0.06 | — | 27.77 | 27.40 | 2.68 | -2504845.00% | 61192.00% | 6724.00% | -109.39% | -5.25 | 706.65% | 0.00% | 0.00% | 215.10% | 3.24 | 3.76 | -243.58 | 1.00 |
| SVRA | Savara Inc. | $6.02 | 1.22B | — | — | — | — | -5.37 | 3.01 | — | -3.38 | -11.82 | 3.20 | 0.00% | — | — | -61.50% | -3224.37% | -49.11% | 0.16 | — | 13.73 | 13.40 | -0.11 | 4545.00% | — | 7352.00% | -17.29% | -6.05 | -2784.35% | 0.00% | 0.00% | 0.19% | -3.35 | -3.88 | — | 3.70 |
| TNGX | Tango Therapeutics, Inc. | $11.14 | 1.23B | +109% | +24,801% | — | — | -1.68 | 1.10 | 5.22 | 0.01 | -16.54 | 1.10 | 100.00% | -346.09% | -309.73% | -57.58% | 436.15% | -36.24% | 0.18 | — | 6.98 | 6.76 | 0.23 | 1019.00% | 1517.00% | 1067.00% | -60.24% | -3.45 | 396.19% | 0.00% | 0.00% | 2.54% | 0.01 | 0.01 | -0.04 | -1.61 |
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
- CEO
- Joseph Todisco
- Employees
- 64
- Beta
- 1.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($77,885.15 ÷ $7.79) − 1 = +999,709.37% (DCF, example).